ATE398124T1 - Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron - Google Patents

Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron

Info

Publication number
ATE398124T1
ATE398124T1 AT03767563T AT03767563T ATE398124T1 AT E398124 T1 ATE398124 T1 AT E398124T1 AT 03767563 T AT03767563 T AT 03767563T AT 03767563 T AT03767563 T AT 03767563T AT E398124 T1 ATE398124 T1 AT E398124T1
Authority
AT
Austria
Prior art keywords
compounds
formula
aldosterone
imidazoä1
methods
Prior art date
Application number
AT03767563T
Other languages
German (de)
English (en)
Inventor
Fariborz Firooznia
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE398124T1 publication Critical patent/ATE398124T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03767563T 2002-11-18 2003-11-17 Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron ATE398124T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42732502P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
ATE398124T1 true ATE398124T1 (de) 2008-07-15

Family

ID=32326521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767563T ATE398124T1 (de) 2002-11-18 2003-11-17 Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron

Country Status (12)

Country Link
US (2) US7223866B2 (enExample)
EP (1) EP1565463B1 (enExample)
JP (1) JP2006508970A (enExample)
CN (1) CN100447142C (enExample)
AT (1) ATE398124T1 (enExample)
AU (1) AU2003292039A1 (enExample)
BR (1) BR0316306A (enExample)
CA (1) CA2505752A1 (enExample)
DE (1) DE60321593D1 (enExample)
ES (1) ES2305520T3 (enExample)
PT (1) PT1565463E (enExample)
WO (1) WO2004046145A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003294748A1 (en) * 2002-12-06 2004-06-30 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
EP1572632B1 (en) * 2002-12-09 2008-08-13 Xention Limited Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
WO2006092430A1 (de) * 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体
CN101910171A (zh) 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) * 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
EP2757882B1 (en) * 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2013043521A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
PE20142358A1 (es) 2012-01-17 2015-01-30 Novartis Ag Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
HRP20180958T1 (hr) 2013-02-14 2018-07-27 Novartis Ag Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu)
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75569C (fi) * 1981-06-22 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av terapeutiskt verkande imidazo/1,5-a/pyridiner.
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
JPS615076A (ja) * 1984-06-19 1986-01-10 Toyama Chem Co Ltd 新規な1,4−ジヒドロピリジン誘導体およびその塩
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5798364A (en) 1992-03-26 1998-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines
US6150347A (en) 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
DE19701257A1 (de) * 1997-01-17 1998-07-23 Hannecke Wolf D Kunststoff Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method

Also Published As

Publication number Publication date
US7223866B2 (en) 2007-05-29
CN1711262A (zh) 2005-12-21
CN100447142C (zh) 2008-12-31
AU2003292039A1 (en) 2004-06-15
US20070197582A1 (en) 2007-08-23
DE60321593D1 (de) 2008-07-24
EP1565463A1 (en) 2005-08-24
US7713991B2 (en) 2010-05-11
EP1565463B1 (en) 2008-06-11
JP2006508970A (ja) 2006-03-16
WO2004046145A1 (en) 2004-06-03
CA2505752A1 (en) 2004-06-03
BR0316306A (pt) 2005-09-27
PT1565463E (pt) 2008-09-10
HK1081540A1 (en) 2006-05-19
ES2305520T3 (es) 2008-11-01
US20060058342A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE398124T1 (de) Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
ATE335744T1 (de) Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
WO2008076336A3 (en) Imidazoles as aldosterone synthase inhibitors
AU2003290335A1 (en) Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
NO20082834L (no) 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
MY149861A (en) Prolyl hydroxylase inhibitors
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
WO2009079412A3 (en) Reverse transcriptase inhibitors
NO20082545L (no) Seksleddede heterocykler anvendbare som serinproteaseinhibitorer
TW200603798A (en) Disalt inhibitors of il-12 production
MX2009002740A (es) Inhibidores de renina.
DE602007008723D1 (de) Selektive rock-proteinkinasehemmer und ihre verwendung
WO2008036216A8 (en) Piperidine derivatives as renin inhibitors
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
BR0316574A (pt) Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
MA28170A1 (fr) Nouveaux derives de ceto-oxadiazole comme inhibiteurs de la cathepsine
PL1732534T3 (pl) Zastosowanie pochodnych amidowych metylenu przy zaburzeniach sercowo-naczyniowych
DK1061803T3 (da) Eprosartansammensætninger
NO20060247L (no) Substituerte spirobenzazepiner
MXPA05013537A (es) Derivados de indol.
ATE310005T1 (de) 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
ATE410235T1 (de) Behandlung von ballastwasser
TW200736264A (en) Thiazolo[4,5-C]pyridine derivatives
DE602004021145D1 (de) NEUE SUBSTITUIERTE THIOPHENPYRIMIDINONDERIVATE ALS INHIBITOREN VON 17ß-HYDROXYSTEROIDDEHYDROGENASE
DE60304047D1 (de) 1-oxa-3-aza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1565463

Country of ref document: EP

REN Ceased due to non-payment of the annual fee